A real-world study of oprinone injection in the treatment of acute heart failure

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200055129

Enrollment

Unknown

Registered

2022-01-01

Start date

2022-01-20

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute heart failure

Interventions

Olprinone group:Olprinone Hydrochloride Injection

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 85 years, no gender limit; 2. Patients admitted to hospital with a clear diagnosis of acute heart failure, and there are indications for the use of inotropic drugs; 3. The doctor has prescribed Operinone injection for the treatment of acute heart failure; 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. There are contraindications to the use of Oprinon injection, including but not limited to previous history of severe heart disease (such as hypertrophic obstructive cardiomyopathy, severe arrhythmia, severe valvular disease, etc.), kidney disease, and liver disease; 2. Poor compliance, unable to cooperate to complete the test; 3. The doctor considers other conditions that are not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
B-type natriuretic peptide/N-terminal pro-B-type natriuretic peptide;	—

Secondary

Measure	Time frame
NYHA classification of cardiac function;Renal function;Mortality;Rehospitalization rate;	—

Countries

China

Contacts

Public ContactZhou Jingmin

Zhongshan Hospital Fudan University

zhou.jingmin@zs-hospital.sh.cn+86 13601954136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026